Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Department of Medicine and Surgery Science, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, Italy.
Invest New Drugs. 2018 Feb;36(1):144-146. doi: 10.1007/s10637-017-0484-6. Epub 2017 Jun 20.
Anti-programmed cell death-1 (PD-1) monoclonal antibodies, such as nivolumab, used for the treatment of several tumors, can trigger effector T-cells against tumor- and self-antigens, leading to the occurrence of different immune-related adverse events. Among them, liver injuries are rare and usually transient. To date, only four cases of immune-related cholangitis in non-small cell lung cancer (NSCLC) patients have been described during nivolumab treatment. Here, we describe laboratory tests, imaging and liver biopsy features that confirm this diagnosis as opposed to other forms of autoimmune liver disease; nevertheless, we also provide evidence of the presence of different clinical-pathological patterns of immune-related cholangitis.
抗程序性细胞死亡蛋白-1（PD-1）单克隆抗体，如 nivolumab，用于治疗多种肿瘤，可引发针对肿瘤和自身抗原的效应 T 细胞，导致不同的免疫相关不良反应。其中，肝损伤较为罕见且通常是短暂的。迄今为止，nivolumab 治疗期间仅描述了 4 例非小细胞肺癌（NSCLC）患者的免疫相关性胆管炎病例。在这里，我们描述了实验室检查、影像学和肝活检特征，这些特征可确诊为免疫相关性胆管炎，而非其他形式的自身免疫性肝病；然而，我们也提供了证据，证明存在不同的免疫相关性胆管炎临床病理模式。
